New version of implanted neuromodulation device for HF launched - Healio

CVRx announced it has launched a next-generation mentation of its neuromodulation instrumentality to dainty HF symptoms.

The instrumentality (Barostim Neo2 IPG) is the 2nd procreation of the archetypal FDA-approved neuromodulation strategy to dainty HF, according to a property merchandise issued by the company.

Compared with the archetypal procreation of the device, the 2nd procreation is 10% smaller, has 20% much artillery beingness and has 1 alternatively of 2 pb ports to simplify the implantation procedure, according to the release.

“The caller Barostim Neo2 offers the aforesaid clinically proven Barostim therapy, but with a much convenient plan for my patients that is smaller and lasts longer,” Michael Hoosien, MD, electrophysiologist astatine Piedmont Atlanta, said successful the release. “We are excited to usage this next-generation strategy to further grow our Barostim program.”

As Healio antecedently reported, the next-generation programmer for the strategy was launched successful July.